SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'GIN'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1FMO_E_ADNE351_1
(CAMP-DEPENDENT
PROTEIN KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
GLY A 249
VAL A 256
ALA A 269
VAL A 299
ASN A 368
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.58A 1fmoE-2hz0A:
23.7		 1fmoE-2hz0A:
24.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.67A 1iepA-2hz0A:
35.0		 1iepA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.67A 1iepA-2hz0A:
35.0		 1iepA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_A_STIA201_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 VAL A 289
VAL A 299
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
 1.03A 1iepA-2hz0A:
35.0		 1iepA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.85A 1iepB-2hz0A:
34.9		 1iepB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
 0.73A 1iepB-2hz0A:
34.9		 1iepB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 7 VAL A 289
VAL A 299
ILE A 313
MET A 318
LEU A 370
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
 0.45A 1iepB-2hz0A:
34.9		 1iepB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 7 VAL A 299
ILE A 313
MET A 318
ARG A 362
LEU A 370
 GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
GIN  A 600 (-4.7A)
 0.71A 1iepB-2hz0A:
34.9		 1iepB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1M17_A_AQ4A999_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.70A 1m17A-2hz0A:
30.9		 1m17A-2hz0A:
36.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.75A 1opjA-2hz0A:
34.5		 1opjA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
 0.62A 1opjA-2hz0A:
34.5		 1opjA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.54A 1opjA-2hz0A:
34.5		 1opjA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
GLY A 321
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.72A 1opjB-2hz0A:
34.1		 1opjB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
GLY A 321
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
 0.63A 1opjB-2hz0A:
34.1		 1opjB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
LYS A 271
VAL A 289
ILE A 313
ARG A 362
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
None
 1.28A 1opjB-2hz0A:
34.1		 1opjB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
ILE A 313
MET A 318
ARG A 362
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.8A)
None
None
 1.05A 1opjB-2hz0A:
34.1		 1opjB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
VAL A 299
THR A 315
GLY A 321
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 0.70A 1t46A-2hz0A:
32.5		 1t46A-2hz0A:
36.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 ALA A 269
GLU A 286
THR A 315
LEU A 354
HIS A 361
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
 0.55A 1uwhA-2hz0A:
28.4		 1uwhA-2hz0A:
31.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
LYS A 271
GLU A 286
THR A 315
LEU A 354
HIS A 361
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
 0.68A 1uwhB-2hz0A:
28.3		 1uwhB-2hz0A:
31.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XBB_A_STIA1_1
(TYROSINE-PROTEIN
KINASE SYK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 9 LEU A 248
VAL A 256
ALA A 269
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-4.7A)
 0.50A 1xbbA-2hz0A:
32.7		 1xbbA-2hz0A:
39.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XKK_A_FMMA91_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
THR A 315
GLY A 321
LEU A 324
ASP A 325
ARG A 328
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
None
None
None
GIN  A 600 (-4.7A)
 0.54A 1xkkA-2hz0A:
29.8		 1xkkA-2hz0A:
34.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XKK_A_FMMA91_2
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 9 LEU A 248
VAL A 256
LYS A 271
LEU A 301
MET A 318
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
None
None
 0.76A 1xkkA-2hz0A:
29.8		 1xkkA-2hz0A:
34.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2EUF_B_LQQB401_1
(CELL DIVISION
PROTEIN KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 256
LYS A 271
VAL A 299
ASN A 368
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.69A 2eufB-2hz0A:
25.6		 2eufB-2hz0A:
26.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.80A 2gqgA-2hz0A:
35.5		 2gqgA-2hz0A:
97.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.91A 2gqgA-2hz0A:
35.5		 2gqgA-2hz0A:
97.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.90A 2gqgA-2hz0A:
35.5		 2gqgA-2hz0A:
97.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.97A 2gqgA-2hz0A:
35.5		 2gqgA-2hz0A:
97.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 2gqgB-2hz0A:
36.9		 2gqgB-2hz0A:
97.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.80A 2hyyA-2hz0A:
35.1		 2hyyA-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.66A 2hyyA-2hz0A:
35.1		 2hyyA-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
LYS A 271
VAL A 289
ILE A 313
ARG A 362
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
None
 1.33A 2hyyA-2hz0A:
35.1		 2hyyA-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
VAL A 299
ILE A 313
ARG A 362
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.97A 2hyyA-2hz0A:
35.1		 2hyyA-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.75A 2hyyB-2hz0A:
35.3		 2hyyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.61A 2hyyB-2hz0A:
35.3		 2hyyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 LEU A 248
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.74A 2hyyB-2hz0A:
35.3		 2hyyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
VAL A 299
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.38A 2hyyB-2hz0A:
35.3		 2hyyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
ILE A 293
VAL A 299
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.74A 2hyyC-2hz0A:
35.5		 2hyyC-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
ILE A 293
VAL A 299
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.55A 2hyyC-2hz0A:
35.5		 2hyyC-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
LYS A 271
VAL A 289
MET A 290
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
 0.80A 2hyyC-2hz0A:
35.5		 2hyyC-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
MET A 290
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
None
 0.38A 2hyyC-2hz0A:
35.5		 2hyyC-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
ILE A 313
THR A 315
PHE A 317
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.82A 2hyyD-2hz0A:
35.2		 2hyyD-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
ILE A 313
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.65A 2hyyD-2hz0A:
35.2		 2hyyD-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITO_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.86A 2itoA-2hz0A:
30.7		 2itoA-2hz0A:
36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITO_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
THR A 315
GLY A 321
ASP A 325
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.69A 2itoA-2hz0A:
30.7		 2itoA-2hz0A:
36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITY_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
GLY A 249
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 1.05A 2ityA-2hz0A:
30.7		 2ityA-2hz0A:
36.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.80A 2itzA-2hz0A:
30.7		 2itzA-2hz0A:
36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.90A 2itzA-2hz0A:
30.7		 2itzA-2hz0A:
36.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 313
THR A 315
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.69A 2oiqA-2hz0A:
32.1		 2oiqA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 313
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 2oiqA-2hz0A:
32.1		 2oiqA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 5 LEU A 248
VAL A 289
MET A 318
ARG A 362
 GIN  A 600 ( 4.6A)
None
None
None
 0.87A 2oiqA-2hz0A:
32.1		 2oiqA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.67A 2pl0A-2hz0A:
30.8		 2pl0A-2hz0A:
46.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2XP2_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 9 LEU A 248
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.85A 2xp2A-2hz0A:
31.2		 2xp2A-2hz0A:
37.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y6O_A_1N1A1892_1
(EPHRIN TYPE-A
RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
GLU A 286
MET A 290
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.69A 2y6oA-2hz0A:
31.9		 2y6oA-2hz0A:
38.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_C_B49C1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 VAL A 256
ALA A 269
MET A 318
GLY A 321
ASP A 325
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
None
GIN  A 600 (-4.7A)
 0.58A 2y7jC-2hz0A:
25.2		 2y7jC-2hz0A:
26.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2YFX_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 8 LEU A 248
ALA A 269
MET A 318
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.83A 2yfxA-2hz0A:
30.6		 2yfxA-2hz0A:
37.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ZJ0_A_2FAA500_2
(ADENOSYLHOMOCYSTEINA
SE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 5 GLN A 300
THR A 315
HIS A 361
LEU A 354
 None
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 ( 4.6A)
 1.23A 2zj0A-2hz0A:
undetectable		 2zj0A-2hz0A:
18.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ZVA_A_1N1A513_1
(TYROSINE-PROTEIN
KINASE LYN)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		12 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
MET A 318
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.83A 2zvaA-2hz0A:
34.2		 2zvaA-2hz0A:
46.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3AOX_A_EMHA901_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 10 LEU A 248
ALA A 269
LYS A 271
VAL A 299
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
None
None
GIN  A 600 (-4.7A)
 0.77A 3aoxA-2hz0A:
30.0		 3aoxA-2hz0A:
35.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3BBT_B_FMMB91_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 VAL A 256
ALA A 269
LEU A 301
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.63A 3bbtB-2hz0A:
29.6		 3bbtB-2hz0A:
34.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3C7Q_A_XINA1172_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
GLY A 249
GLU A 258
ALA A 269
LYS A 271
VAL A 299
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
None
None
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.62A 3c7qA-2hz0A:
29.8		 3c7qA-2hz0A:
37.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 10 LEU A 248
VAL A 256
LYS A 271
ILE A 313
PHE A 317
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
 0.56A 3cs9A-2hz0A:
35.0		 3cs9A-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 LEU A 248
VAL A 256
VAL A 299
ILE A 313
PHE A 317
VAL A 379
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.5A)
 0.69A 3cs9A-2hz0A:
35.0		 3cs9A-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 10 VAL A 299
ILE A 313
PHE A 317
VAL A 379
ASP A 381
 GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.9A)
 0.67A 3cs9A-2hz0A:
35.0		 3cs9A-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.57A 3cs9A-2hz0A:
35.0		 3cs9A-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
GLY A 321
HIS A 361
LEU A 370
ALA A 380
 None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.72A 3cs9A-2hz0A:
35.0		 3cs9A-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
GLY A 321
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-3.1A)
 0.56A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 GLU A 286
MET A 290
LEU A 298
THR A 315
GLY A 321
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.74A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 298
THR A 315
GLY A 321
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.71A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 289
ILE A 293
LEU A 298
THR A 315
GLY A 321
HIS A 361
ALA A 380
 None
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
 0.76A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 9 LEU A 248
VAL A 256
LYS A 271
VAL A 299
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
 0.67A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 9 LEU A 248
VAL A 256
VAL A 299
ILE A 313
PHE A 359
LEU A 370
VAL A 379
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.5A)
 0.76A 3cs9B-2hz0A:
34.5		 3cs9B-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 ALA A 269
GLU A 286
VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
PHE A 317
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.90A 3cs9C-2hz0A:
34.7		 3cs9C-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 9 LEU A 248
VAL A 256
VAL A 299
ILE A 313
MET A 318
VAL A 379
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.5A)
 0.67A 3cs9C-2hz0A:
34.7		 3cs9C-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
PHE A 317
GLY A 321
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
 0.60A 3cs9D-2hz0A:
32.8		 3cs9D-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
VAL A 289
MET A 290
ILE A 293
LEU A 298
THR A 315
PHE A 317
GLY A 321
HIS A 361
ALA A 380
 GIN  A 600 (-3.1A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
 0.69A 3cs9D-2hz0A:
32.8		 3cs9D-2hz0A:
98.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3EYG_A_MI1A1_1
(TYROSINE-PROTEIN
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
GLY A 249
GLY A 251
GLY A 254
VAL A 256
ALA A 269
LYS A 271
ASN A 368
LEU A 370
 GIN  A 600 ( 4.6A)
None
None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-4.7A)
 0.55A 3eygA-2hz0A:
32.0		 3eygA-2hz0A:
36.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3FUP_B_MI1B1_1
(TYROSINE-PROTEIN
KINASE JAK2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
GLY A 249
GLY A 251
VAL A 256
ALA A 269
LYS A 271
VAL A 299
LEU A 370
 GIN  A 600 ( 4.6A)
None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
 0.49A 3fupB-2hz0A:
32.0		 3fupB-2hz0A:
36.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0E_A_B49A9000_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 11 LEU A 248
VAL A 256
ALA A 269
VAL A 299
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.58A 3g0eA-2hz0A:
30.2		 3g0eA-2hz0A:
33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
VAL A 256
ALA A 269
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.58A 3g0fA-2hz0A:
31.2		 3g0fA-2hz0A:
33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 LEU A 248
VAL A 256
ALA A 269
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.49A 3g0fB-2hz0A:
31.8		 3g0fB-2hz0A:
33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.66A 3g5dA-2hz0A:
32.9		 3g5dA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_B_1N1B1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.80A 3g5dB-2hz0A:
32.9		 3g5dB-2hz0A:
48.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GP0_A_NILA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 11)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
THR A 315
HIS A 361
ASP A 381
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 1.13A 3gp0A-2hz0A:
21.8		 3gp0A-2hz0A:
25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GP0_A_NILA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 11)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 VAL A 256
ALA A 269
GLU A 286
THR A 315
HIS A 361
PHE A 382
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.0A)
 1.15A 3gp0A-2hz0A:
21.8		 3gp0A-2hz0A:
25.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.83A 3gvuA-2hz0A:
35.0		 3gvuA-2hz0A:
86.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.65A 3gvuA-2hz0A:
35.0		 3gvuA-2hz0A:
86.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
LEU A 298
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.40A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
MET A 290
ILE A 293
LEU A 298
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.65A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 GLU A 286
MET A 290
ILE A 293
LEU A 298
VAL A 299
LEU A 370
ALA A 380
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.59A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 GLU A 286
MET A 290
LEU A 298
VAL A 299
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.78A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 MET A 290
ILE A 293
LEU A 298
VAL A 299
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.69A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 MET A 290
LEU A 298
VAL A 299
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.2A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.73A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 LEU A 248
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.77A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 LEU A 248
VAL A 289
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.8A)
None
 0.30A 3ik3A-2hz0A:
34.3		 3ik3A-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
LEU A 298
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.39A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
MET A 290
ILE A 293
LEU A 298
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 GLU A 286
MET A 290
ILE A 293
LEU A 298
VAL A 299
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.81A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 MET A 290
ILE A 293
LEU A 298
VAL A 299
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.75A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 LEU A 248
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.73A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 LEU A 248
VAL A 289
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.8A)
None
 0.31A 3ik3B-2hz0A:
33.9		 3ik3B-2hz0A:
98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K54_A_1N1A1_1
(TYROSINE-PROTEIN
KINASE BTK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.80A 3k54A-2hz0A:
30.5		 3k54A-2hz0A:
44.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.79A 3k5vA-2hz0A:
34.4		 3k5vA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.67A 3k5vA-2hz0A:
34.4		 3k5vA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 LEU A 248
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.69A 3k5vA-2hz0A:
34.4		 3k5vA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
VAL A 299
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.42A 3k5vA-2hz0A:
34.4		 3k5vA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.76A 3k5vB-2hz0A:
34.0		 3k5vB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 3k5vB-2hz0A:
34.0		 3k5vB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 LEU A 248
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.76A 3k5vB-2hz0A:
34.0		 3k5vB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
VAL A 299
ILE A 313
MET A 318
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.43A 3k5vB-2hz0A:
34.0		 3k5vB-2hz0A:
97.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LFA_A_1N1A361_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 8 ALA A 269
LYS A 271
GLU A 286
THR A 315
MET A 318
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
 0.56A 3lfaA-2hz0A:
19.8		 3lfaA-2hz0A:
27.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LXK_A_MI1A1125_1
(TYROSINE-PROTEIN
KINASE JAK3)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
GLY A 249
VAL A 256
ALA A 269
LYS A 271
VAL A 299
ALA A 380
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.1A)
 0.65A 3lxkA-2hz0A:
33.0		 3lxkA-2hz0A:
33.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3LXK_A_MI1A1125_1
(TYROSINE-PROTEIN
KINASE JAK3)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
GLY A 249
VAL A 256
ALA A 269
VAL A 299
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.65A 3lxkA-2hz0A:
33.0		 3lxkA-2hz0A:
33.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MIY_A_B49A1_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 11 ALA A 269
LYS A 271
VAL A 299
PHE A 317
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
 0.57A 3miyA-2hz0A:
31.8		 3miyA-2hz0A:
42.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MIY_B_B49B2_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 9 ALA A 269
LYS A 271
PHE A 317
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
 0.64A 3miyB-2hz0A:
31.6		 3miyB-2hz0A:
42.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.79A 3ms9A-2hz0A:
34.6		 3ms9A-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.68A 3ms9A-2hz0A:
34.6		 3ms9A-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 VAL A 289
VAL A 299
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
 0.79A 3ms9A-2hz0A:
34.6		 3ms9A-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.75A 3ms9B-2hz0A:
34.9		 3ms9B-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.66A 3ms9B-2hz0A:
34.9		 3ms9B-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_B_STIB1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 VAL A 289
VAL A 299
ILE A 313
MET A 318
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.27A 3ms9B-2hz0A:
34.9		 3ms9B-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.77A 3mssA-2hz0A:
34.6		 3mssA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.67A 3mssA-2hz0A:
34.6		 3mssA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 VAL A 289
VAL A 299
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
 0.83A 3mssA-2hz0A:
34.6		 3mssA-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.78A 3mssB-2hz0A:
34.6		 3mssB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
 0.68A 3mssB-2hz0A:
34.6		 3mssB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.59A 3mssB-2hz0A:
34.6		 3mssB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.61A 3mssB-2hz0A:
34.6		 3mssB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 7 VAL A 289
VAL A 299
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
 1.04A 3mssB-2hz0A:
34.6		 3mssB-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.79A 3mssC-2hz0A:
34.6		 3mssC-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.68A 3mssC-2hz0A:
34.6		 3mssC-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_C_STIC1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 VAL A 289
VAL A 299
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
None
 0.85A 3mssC-2hz0A:
34.6		 3mssC-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.76A 3mssD-2hz0A:
34.7		 3mssD-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.67A 3mssD-2hz0A:
34.7		 3mssD-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 VAL A 256
LYS A 271
VAL A 289
ILE A 313
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
 0.61A 3mssD-2hz0A:
34.7		 3mssD-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 VAL A 256
VAL A 289
VAL A 299
ILE A 313
MET A 318
 GIN  A 600 ( 4.7A)
None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 0.42A 3mssD-2hz0A:
34.7		 3mssD-2hz0A:
97.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
MET A 290
VAL A 299
THR A 315
GLY A 321
GLU A 329
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 1.25A 3octA-2hz0A:
31.8		 3octA-2hz0A:
45.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.34A 3oezA-2hz0A:
31.7		 3oezA-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.67A 3oezA-2hz0A:
31.7		 3oezA-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
VAL A 289
MET A 290
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.56A 3oezB-2hz0A:
31.8		 3oezB-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
GLU A 286
VAL A 289
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.76A 3oezB-2hz0A:
31.8		 3oezB-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 GLU A 286
MET A 290
ILE A 313
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.80A 3oezB-2hz0A:
31.8		 3oezB-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
LYS A 271
VAL A 289
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.72A 3oezB-2hz0A:
31.8		 3oezB-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
VAL A 289
MET A 290
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.59A 3oezB-2hz0A:
31.8		 3oezB-2hz0A:
48.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_A_1N1A1000_1
(P38A)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 249
VAL A 256
ALA A 269
LYS A 271
THR A 315
LEU A 370
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
 1.02A 3ohtA-2hz0A:
16.6		 3ohtA-2hz0A:
24.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_B_1N1B1000_1
(P38A)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 249
VAL A 256
ALA A 269
LYS A 271
THR A 315
GLY A 321
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
 0.71A 3ohtB-2hz0A:
16.6		 3ohtB-2hz0A:
24.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
LEU A 298
VAL A 299
THR A 315
GLY A 321
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.76A 3oxzA-2hz0A:
34.3		 3oxzA-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 9 LEU A 248
LYS A 271
VAL A 289
ILE A 313
ARG A 362
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
 1.07A 3oxzA-2hz0A:
34.3		 3oxzA-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 9 LEU A 248
VAL A 289
ILE A 313
MET A 318
ARG A 362
LEU A 370
VAL A 379
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.8A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.5A)
 0.76A 3oxzA-2hz0A:
34.3		 3oxzA-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.44A 3pyyA-2hz0A:
34.0		 3pyyA-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
ALA A 380
ASP A 381
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.65A 3pyyA-2hz0A:
34.0		 3pyyA-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
 0.56A 3pyyA-2hz0A:
34.0		 3pyyA-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
THR A 315
PHE A 317
GLY A 321
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
 0.54A 3pyyA-2hz0A:
34.0		 3pyyA-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_2
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 VAL A 289
VAL A 299
ILE A 313
ARG A 362
 None
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
 1.07A 3pyyA-2hz0A:
34.0		 3pyyA-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.70A 3pyyB-2hz0A:
34.2		 3pyyB-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.49A 3pyyB-2hz0A:
34.2		 3pyyB-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_2
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 5 LYS A 271
VAL A 289
ILE A 313
ARG A 362
 GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.8A)
None
 1.22A 3pyyB-2hz0A:
34.2		 3pyyB-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_2
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 5 VAL A 289
ILE A 313
MET A 318
ARG A 362
 None
GIN  A 600 (-3.8A)
None
None
 0.74A 3pyyB-2hz0A:
34.2		 3pyyB-2hz0A:
95.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.84A 3qlgA-2hz0A:
31.5		 3qlgA-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.91A 3qlgA-2hz0A:
31.5		 3qlgA-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_B_1N1B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.79A 3qlgB-2hz0A:
32.6		 3qlgB-2hz0A:
48.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.65A 3sxrA-2hz0A:
32.2		 3sxrA-2hz0A:
41.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_B_1N1B2_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
MET A 290
VAL A 299
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.57A 3sxrB-2hz0A:
32.0		 3sxrB-2hz0A:
41.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
PHE A 317
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
 0.77A 3ue4A-2hz0A:
35.7		 3ue4A-2hz0A:
98.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
VAL A 299
ILE A 313
THR A 315
PHE A 317
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
 0.65A 3ue4A-2hz0A:
35.7		 3ue4A-2hz0A:
98.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.74A 3ue4B-2hz0A:
35.5		 3ue4B-2hz0A:
98.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.65A 3ue4B-2hz0A:
35.5		 3ue4B-2hz0A:
98.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UG2_A_IREA1_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
MET A 318
GLY A 321
ASP A 325
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
None
None
GIN  A 600 (-4.7A)
 0.83A 3ug2A-2hz0A:
30.3		 3ug2A-2hz0A:
35.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3V5W_A_8PRA701_1
(G-PROTEIN COUPLED
RECEPTOR KINASE 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 GLY A 251
GLY A 254
VAL A 256
ALA A 269
LYS A 271
VAL A 299
LEU A 370
 None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
 0.97A 3v5wA-2hz0A:
6.3		 3v5wA-2hz0A:
16.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WZD_A_LEVA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
GLY A 321
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
 0.39A 3wzdA-2hz0A:
30.5		 3wzdA-2hz0A:
38.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WZE_A_BAXA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
ILE A 293
PHE A 317
GLY A 321
LEU A 354
HIS A 361
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.3A)
None
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
 0.79A 3wzeA-2hz0A:
32.2		 3wzeA-2hz0A:
38.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WZE_A_BAXA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 8 VAL A 299
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 0.43A 3wzeA-2hz0A:
32.2		 3wzeA-2hz0A:
38.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
ALA A 380
ASP A 381
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 1.09A 3zosA-2hz0A:
29.9		 3zosA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
GLU A 286
THR A 315
LEU A 354
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.77A 3zosA-2hz0A:
29.9		 3zosA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
ALA A 380
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.0A)
 1.08A 3zosA-2hz0A:
29.9		 3zosA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
THR A 315
LEU A 354
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.64A 3zosA-2hz0A:
29.9		 3zosA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 1.02A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 1.12A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
THR A 315
LEU A 354
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.76A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.98A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
GLU A 286
THR A 315
HIS A 361
ARG A 362
LEU A 370
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.0A)
 1.10A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
GLU A 286
THR A 315
LEU A 354
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 3zosB-2hz0A:
30.1		 3zosB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AG8_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
VAL A 299
PHE A 317
GLY A 321
LEU A 370
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.0A)
 0.41A 4ag8A-2hz0A:
32.4		 4ag8A-2hz0A:
37.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AGC_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
GLY A 321
LEU A 370
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.0A)
 0.42A 4agcA-2hz0A:
31.6		 4agcA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 ALA A 269
LYS A 271
VAL A 299
GLY A 321
LEU A 370
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.0A)
 0.80A 4agdA-2hz0A:
30.7		 4agdA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 ALA A 269
VAL A 299
PHE A 317
GLY A 321
LEU A 370
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.0A)
 0.65A 4agdA-2hz0A:
30.7		 4agdA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
ALA A 269
LYS A 271
VAL A 299
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
None
GIN  A 600 (-4.7A)
 0.62A 4agdA-2hz0A:
30.7		 4agdA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
ALA A 269
VAL A 299
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.47A 4agdA-2hz0A:
30.7		 4agdA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANQ_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 9 LEU A 248
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.92A 4anqA-2hz0A:
30.8		 4anqA-2hz0A:
35.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANS_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 9 LEU A 248
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.96A 4ansA-2hz0A:
30.7		 4ansA-2hz0A:
35.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ASD_A_BAXA1500_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
PHE A 317
GLY A 321
LEU A 354
HIS A 361
PHE A 382
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.0A)
 0.69A 4asdA-2hz0A:
31.8		 4asdA-2hz0A:
35.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_A_STIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.74A 4bkjA-2hz0A:
30.0		 4bkjA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_A_STIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.83A 4bkjA-2hz0A:
30.0		 4bkjA-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.63A 4bkjB-2hz0A:
30.2		 4bkjB-2hz0A:
38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.67A 4bkjB-2hz0A:
30.2		 4bkjB-2hz0A:
38.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.77A 4c8bA-2hz0A:
26.4		 4c8bA-2hz0A:
26.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
GLY A 249
GLY A 383
VAL A 256
ALA A 269
LEU A 370
 GIN  A 600 ( 4.6A)
None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.7A)
 0.79A 4ckiA-2hz0A:
33.5		 4ckiA-2hz0A:
38.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
GLY A 249
VAL A 256
ALA A 269
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-4.7A)
 0.39A 4ckiA-2hz0A:
33.5		 4ckiA-2hz0A:
38.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKJ_A_ADNA2014_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 LEU A 248
GLY A 249
GLY A 251
VAL A 256
ALA A 269
LEU A 370
 GIN  A 600 ( 4.6A)
None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.7A)
 0.60A 4ckjA-2hz0A:
33.4		 4ckjA-2hz0A:
38.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
THR A 315
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 0.90A 4csvA-2hz0A:
33.2		 4csvA-2hz0A:
67.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.71A 4csvA-2hz0A:
33.2		 4csvA-2hz0A:
67.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.62A 4csvA-2hz0A:
33.2		 4csvA-2hz0A:
67.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HJO_A_AQ4A1001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.69A 4hjoA-2hz0A:
30.1		 4hjoA-2hz0A:
35.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KS8_A_B49A701_1
(SERINE/THREONINE-PRO
TEIN KINASE PAK 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 10 ALA A 269
VAL A 299
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.40A 4ks8A-2hz0A:
25.7		 4ks8A-2hz0A:
24.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4L9I_B_8PRB601_1
(RHODOPSIN KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 8 GLY A 251
VAL A 256
ALA A 269
LYS A 271
LEU A 370
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.7A)
 0.70A 4l9iB-2hz0A:
22.0		 4l9iB-2hz0A:
22.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MKC_A_4MKA1503_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
GLY A 250
VAL A 256
ALA A 269
LYS A 271
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.97A 4mkcA-2hz0A:
31.2		 4mkcA-2hz0A:
33.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.80A 4mxoA-2hz0A:
32.8		 4mxoA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.85A 4mxoA-2hz0A:
32.8		 4mxoA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
 0.94A 4mxoA-2hz0A:
32.8		 4mxoA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
VAL A 299
ILE A 313
THR A 315
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.81A 4mxoB-2hz0A:
32.6		 4mxoB-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.66A 4mxoB-2hz0A:
32.6		 4mxoB-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.72A 4mxoB-2hz0A:
32.6		 4mxoB-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
VAL A 299
ILE A 313
THR A 315
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.83A 4mxoB-2hz0A:
32.6		 4mxoB-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 1.00A 4mxxA-2hz0A:
32.6		 4mxxA-2hz0A:
48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
GLU A 286
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.93A 4mxxA-2hz0A:
32.6		 4mxxA-2hz0A:
48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.97A 4mxxA-2hz0A:
32.6		 4mxxA-2hz0A:
48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.66A 4mxxB-2hz0A:
30.7		 4mxxB-2hz0A:
48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
VAL A 299
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.74A 4mxxB-2hz0A:
30.7		 4mxxB-2hz0A:
48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXY_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
VAL A 299
ILE A 313
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.87A 4mxyA-2hz0A:
33.3		 4mxyA-2hz0A:
47.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXZ_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
VAL A 299
ILE A 313
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.87A 4mxzA-2hz0A:
33.3		 4mxzA-2hz0A:
47.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4O0U_A_ADNA501_1
(AURORA KINASE A)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 VAL A 256
ALA A 269
LYS A 271
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.7A)
 0.63A 4o0uA-2hz0A:
6.5		 4o0uA-2hz0A:
27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4O0W_A_ADNA501_1
(AURORA KINASE A)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
GLY A 249
VAL A 256
ALA A 269
LEU A 370
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.7A)
 0.43A 4o0wA-2hz0A:
25.2		 4o0wA-2hz0A:
27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OGR_I_ADNI401_1
(CYCLIN-DEPENDENT
KINASE 9)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 9 GLY A 383
VAL A 256
ALA A 269
ASN A 368
LEU A 370
ASP A 381
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.90A 4ogrI-2hz0A:
24.7		 4ogrI-2hz0A:
26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OTI_A_MI1A1001_1
(SERINE/THREONINE-PRO
TEIN KINASE N1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
GLY A 249
GLY A 251
GLY A 254
VAL A 256
ALA A 269
VAL A 299
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
None
None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.51A 4otiA-2hz0A:
19.6		 4otiA-2hz0A:
26.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4OTW_A_DB8A1101_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-3)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
LYS A 271
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.76A 4otwA-2hz0A:
29.9		 4otwA-2hz0A:
36.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4OTW_A_DB8A1101_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-3)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
VAL A 299
THR A 315
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.76A 4otwA-2hz0A:
29.9		 4otwA-2hz0A:
36.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
ILE A 313
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.79A 4qmnA-2hz0A:
26.5		 4qmnA-2hz0A:
26.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QRC_A_0LIA802_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
MET A 290
ARG A 362
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 1.09A 4qrcA-2hz0A:
31.7		 4qrcA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QRC_A_0LIA802_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
MET A 290
LEU A 354
ARG A 362
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.1A)
 0.82A 4qrcA-2hz0A:
31.7		 4qrcA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QRC_A_0LIA802_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 8 LEU A 248
VAL A 256
HIS A 361
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
 0.58A 4qrcA-2hz0A:
31.7		 4qrcA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 0.72A 4r7iA-2hz0A:
32.0		 4r7iA-2hz0A:
34.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
PHE A 317
MET A 318
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.57A 4twpA-2hz0A:
35.7		 4twpA-2hz0A:
99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
PHE A 317
MET A 318
GLY A 321
ASN A 368
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.3A)
None
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.65A 4twpA-2hz0A:
35.7		 4twpA-2hz0A:
99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
PHE A 317
MET A 318
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.59A 4twpB-2hz0A:
36.2		 4twpB-2hz0A:
99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
PHE A 317
MET A 318
GLY A 321
ASN A 368
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.3A)
None
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.62A 4twpB-2hz0A:
36.2		 4twpB-2hz0A:
99.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TYJ_A_0LIA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.88A 4tyjA-2hz0A:
31.9		 4tyjA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
LYS A 271
THR A 315
GLY A 321
HIS A 361
LEU A 370
ASP A 381
PHE A 382
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
GIN  A 600 (-4.0A)
 0.76A 4u0iA-2hz0A:
32.1		 4u0iA-2hz0A:
35.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 11 LEU A 248
GLY A 251
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.77A 4u5jA-2hz0A:
34.5		 4u5jA-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 9 LEU A 248
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
 0.49A 4u5jB-2hz0A:
33.0		 4u5jB-2hz0A:
48.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
GLU A 286
ILE A 293
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.53A 4uxqA-2hz0A:
32.0		 4uxqA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
ILE A 293
LEU A 354
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.5A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.92A 4uxqA-2hz0A:
32.0		 4uxqA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ILE A 293
LEU A 354
HIS A 361
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-4.5A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.90A 4uxqA-2hz0A:
32.0		 4uxqA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 LEU A 354
HIS A 361
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.62A 4uxqA-2hz0A:
32.0		 4uxqA-2hz0A:
40.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_A_0LIA1776_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
LEU A 354
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 1.06A 4v01A-2hz0A:
30.3		 4v01A-2hz0A:
40.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_B_0LIB1770_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
LEU A 354
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.86A 4v01B-2hz0A:
30.8		 4v01B-2hz0A:
40.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_A_0LIA1772_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
LEU A 354
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 1.01A 4v04A-2hz0A:
29.6		 4v04A-2hz0A:
40.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_B_0LIB1771_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
GLU A 286
LEU A 354
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 ( 4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.91A 4v04B-2hz0A:
30.2		 4v04B-2hz0A:
40.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 11 ALA A 269
THR A 315
MET A 318
GLY A 321
ASN A 368
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.63A 4wa9A-2hz0A:
31.1		 4wa9A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
ALA A 269
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.71A 4wa9A-2hz0A:
31.1		 4wa9A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 256
ALA A 269
LYS A 271
THR A 315
PHE A 317
MET A 318
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.63A 4wa9B-2hz0A:
34.9		 4wa9B-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 256
ALA A 269
THR A 315
PHE A 317
MET A 318
GLY A 321
ASN A 368
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.64A 4wa9B-2hz0A:
34.9		 4wa9B-2hz0A:
99.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WBO_C_ANWC601_0
(RHODOPSIN KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 6 LEU A 248
ALA A 269
MET A 318
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
None
GIN  A 600 (-4.7A)
 0.60A 4wboC-2hz0A:
21.9		 4wboC-2hz0A:
22.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WKQ_A_IREA1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.76A 4wkqA-2hz0A:
31.0		 4wkqA-2hz0A:
36.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WKQ_A_IREA1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
THR A 315
GLY A 321
ASP A 325
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.82A 4wkqA-2hz0A:
31.0		 4wkqA-2hz0A:
36.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_A_1N1A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		12 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.77A 4xeyA-2hz0A:
36.0		 4xeyA-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.71A 4xeyB-2hz0A:
35.4		 4xeyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.65A 4xeyB-2hz0A:
35.4		 4xeyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
MET A 290
ILE A 313
PHE A 317
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.69A 4xeyB-2hz0A:
35.4		 4xeyB-2hz0A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
ALA A 269
GLU A 286
MET A 290
VAL A 299
THR A 315
MET A 318
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.64A 4xliA-2hz0A:
36.0		 4xliA-2hz0A:
93.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_B_1N1B600_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		11 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.72A 4xliB-2hz0A:
36.1		 4xliB-2hz0A:
93.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XV2_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 VAL A 256
ALA A 269
LYS A 271
THR A 315
ASP A 381
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.60A 4xv2A-2hz0A:
27.7		 4xv2A-2hz0A:
30.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ZAU_A_YY3A1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 8 LEU A 248
GLY A 249
VAL A 256
ALA A 269
MET A 318
GLY A 321
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
 0.64A 4zauA-2hz0A:
30.5		 4zauA-2hz0A:
36.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAA_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 9 LEU A 248
VAL A 256
ALA A 269
MET A 318
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.80A 5aaaA-2hz0A:
31.1		 5aaaA-2hz0A:
37.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAB_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 10 LEU A 248
VAL A 256
ALA A 269
LYS A 271
MET A 318
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.89A 5aabA-2hz0A:
30.8		 5aabA-2hz0A:
37.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAC_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 10 LEU A 248
VAL A 256
ALA A 269
LYS A 271
MET A 318
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
None
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 1.04A 5aacA-2hz0A:
30.7		 5aacA-2hz0A:
37.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AJQ_A_DB8A800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
ALA A 269
LYS A 271
PHE A 317
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 1.16A 5ajqA-2hz0A:
23.4		 5ajqA-2hz0A:
29.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AJQ_A_DB8A800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
ALA A 269
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.65A 5ajqA-2hz0A:
23.4		 5ajqA-2hz0A:
29.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AJQ_A_DB8A800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
GLY A 249
ALA A 269
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-3.1A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.84A 5ajqA-2hz0A:
23.4		 5ajqA-2hz0A:
29.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AJQ_B_DB8B800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 ALA A 269
PHE A 317
GLY A 321
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.58A 5ajqB-2hz0A:
23.8		 5ajqB-2hz0A:
29.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BVW_A_1N1A1009_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
GLY A 321
LEU A 370
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.60A 5bvwA-2hz0A:
30.6		 5bvwA-2hz0A:
37.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_A_1N1A501_1
(PROTEIN-TYROSINE
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
VAL A 256
ALA A 269
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.61A 5h2uA-2hz0A:
31.8		 5h2uA-2hz0A:
42.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
VAL A 256
ALA A 269
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.66A 5h2uB-2hz0A:
32.0		 5h2uB-2hz0A:
42.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_C_1N1C501_1
(PROTEIN-TYROSINE
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.58A 5h2uC-2hz0A:
31.8		 5h2uC-2hz0A:
42.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_D_1N1D504_1
(PROTEIN-TYROSINE
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.54A 5h2uD-2hz0A:
31.9		 5h2uD-2hz0A:
42.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_D_1N1D504_1
(PROTEIN-TYROSINE
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
VAL A 256
ALA A 269
ILE A 313
GLY A 321
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
None
GIN  A 600 (-4.7A)
 0.56A 5h2uD-2hz0A:
31.9		 5h2uD-2hz0A:
42.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 VAL A 256
ALA A 269
ILE A 313
THR A 315
ASP A 325
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
 0.63A 5hesA-2hz0A:
8.1		 5hesA-2hz0A:
32.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
ASP A 325
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
 0.56A 5hesB-2hz0A:
25.3		 5hesB-2hz0A:
32.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 GLY A 383
VAL A 256
ALA A 269
LYS A 271
THR A 315
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
 0.69A 5hieA-2hz0A:
26.7		 5hieA-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
 0.43A 5hieA-2hz0A:
26.7		 5hieA-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 GLY A 383
VAL A 256
ALA A 269
LYS A 271
THR A 315
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
 0.70A 5hieB-2hz0A:
27.0		 5hieB-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
 0.43A 5hieB-2hz0A:
27.0		 5hieB-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 249
GLY A 383
VAL A 256
ALA A 269
LYS A 271
THR A 315
 None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
 0.87A 5hieC-2hz0A:
26.6		 5hieC-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 250
VAL A 256
ALA A 269
LYS A 271
THR A 315
ASP A 381
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.87A 5hieC-2hz0A:
26.6		 5hieC-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_C_P06C801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 383
VAL A 256
ALA A 269
LYS A 271
THR A 315
ASP A 381
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.9A)
 0.76A 5hieC-2hz0A:
26.6		 5hieC-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 GLY A 383
VAL A 256
ALA A 269
LYS A 271
THR A 315
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
 0.70A 5hieD-2hz0A:
26.4		 5hieD-2hz0A:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
 0.43A 5hieD-2hz0A:
26.4		 5hieD-2hz0A:
29.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 ALA A 269
ILE A 313
THR A 315
GLY A 321
GLU A 329
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.57A 5i9xA-2hz0A:
31.1		 5i9xA-2hz0A:
37.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9Y_A_1N1A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
LYS A 271
MET A 290
THR A 315
GLY A 321
GLU A 329
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.74A 5i9yA-2hz0A:
30.9		 5i9yA-2hz0A:
37.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_G_AZ1G2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 GLY A 249
GLY A 251
VAL A 256
LYS A 271
 None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
 0.43A 5izjA-2hz0A:
22.8		 5izjA-2hz0A:
24.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J5X_B_AZ1B2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAL-DAR-DAR-
DAR-DAR)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 7 GLY A 249
GLY A 251
VAL A 256
LYS A 271
 None
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
 0.48A 5j5xA-2hz0A:
23.1		 5j5xA-2hz0A:
24.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L2I_A_LQQA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 249
VAL A 256
ALA A 269
VAL A 299
LEU A 370
ALA A 380
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.47A 5l2iA-2hz0A:
5.9		 5l2iA-2hz0A:
25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L2T_A_6ZZA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 249
VAL A 256
ALA A 269
VAL A 299
LEU A 370
ALA A 380
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.74A 5l2tA-2hz0A:
23.2		 5l2tA-2hz0A:
25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LVN_A_ADNA402_1
(3-PHOSPHOINOSITIDE-D
EPENDENT PROTEIN
KINASE 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 11 LEU A 248
GLY A 249
VAL A 256
ALA A 269
VAL A 299
LEU A 370
 GIN  A 600 ( 4.6A)
None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
 0.55A 5lvnA-2hz0A:
24.7		 5lvnA-2hz0A:
26.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_B_ADNB401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 9 GLY A 249
VAL A 256
ALA A 269
MET A 318
ASN A 322
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
 0.72A 5lw1B-2hz0A:
20.8		 5lw1B-2hz0A:
15.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_E_ADNE401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 10 GLY A 249
VAL A 256
ALA A 269
MET A 318
ASN A 322
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
 0.71A 5lw1E-2hz0A:
20.4		 5lw1E-2hz0A:
15.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_H_ADNH401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 9 GLY A 249
VAL A 256
ALA A 269
MET A 318
ASN A 322
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
None
None
 0.59A 5lw1H-2hz0A:
20.6		 5lw1H-2hz0A:
15.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 GLU A 286
ILE A 313
PHE A 317
MET A 318
GLY A 321
PHE A 382
 GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
None
None
GIN  A 600 (-4.0A)
 0.87A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 10 LEU A 248
VAL A 256
GLU A 286
ILE A 313
PHE A 317
MET A 318
GLY A 321
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
None
None
 0.51A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 10 LEU A 248
VAL A 256
LYS A 271
GLU A 286
ILE A 313
PHE A 317
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
 0.67A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 ALA A 269
VAL A 289
MET A 290
ILE A 293
LEU A 298
VAL A 299
LEU A 370
ALA A 380
 GIN  A 600 (-3.1A)
None
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.56A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 LEU A 298
VAL A 299
HIS A 361
ALA A 380
ASP A 381
 GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.55A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 12 MET A 290
LEU A 298
VAL A 299
ALA A 380
ASP A 381
 GIN  A 600 (-3.2A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.69A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 289
ILE A 293
LEU A 298
VAL A 299
HIS A 361
LEU A 370
ALA A 380
 None
GIN  A 600 (-4.5A)
GIN  A 600 (-4.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.70A 5mo4A-2hz0A:
7.5		 5mo4A-2hz0A:
99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5P9I_A_1E8A701_1
(TYROSINE-PROTEIN
KINASE BTK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 GLY A 383
VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
 None
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
 0.90A 5p9iA-2hz0A:
31.2		 5p9iA-2hz0A:
44.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5P9I_A_1E8A701_1
(TYROSINE-PROTEIN
KINASE BTK)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 VAL A 256
ALA A 269
ILE A 313
THR A 315
GLY A 321
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
 0.78A 5p9iA-2hz0A:
31.2		 5p9iA-2hz0A:
44.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TE0_A_XINA401_1
(AP2-ASSOCIATED
PROTEIN KINASE 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 ALA A 269
GLU A 286
MET A 290
VAL A 299
PHE A 317
GLY A 321
LEU A 370
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-4.3A)
None
GIN  A 600 (-4.7A)
 0.49A 5te0A-2hz0A:
23.8		 5te0A-2hz0A:
23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCV_A_1N1A404_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
GLU A 286
VAL A 299
THR A 315
GLY A 321
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
None
 0.86A 5vcvA-2hz0A:
24.7		 5vcvA-2hz0A:
22.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCV_A_1N1A404_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
ALA A 269
LYS A 271
GLU A 286
THR A 315
GLY A 321
 GIN  A 600 ( 4.6A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
 0.96A 5vcvA-2hz0A:
24.7		 5vcvA-2hz0A:
22.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
THR A 315
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
 0.69A 5vcyA-2hz0A:
24.7		 5vcyA-2hz0A:
22.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y80_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
THR A 315
GLY A 321
LEU A 370
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.64A 5y80A-2hz0A:
22.8		 5y80A-2hz0A:
14.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y80_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
THR A 315
GLY A 321
ASP A 381
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.4A)
None
GIN  A 600 (-4.9A)
 0.78A 5y80A-2hz0A:
22.8		 5y80A-2hz0A:
14.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_A_LEVA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
GLY A 321
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
None
GIN  A 600 (-3.1A)
 0.67A 5zv2A-2hz0A:
30.0		 5zv2A-2hz0A:
16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_B_LEVB801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
GLY A 321
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
None
GIN  A 600 (-3.1A)
 0.65A 5zv2B-2hz0A:
29.8		 5zv2B-2hz0A:
16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_B_LEVB801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
GLY A 321
ALA A 380
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
None
GIN  A 600 (-3.1A)
 0.54A 5zv2B-2hz0A:
29.8		 5zv2B-2hz0A:
16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.58A 6bsdA-2hz0A:
29.9		 6bsdA-2hz0A:
13.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 VAL A 256
ALA A 269
LYS A 271
ILE A 313
THR A 315
MET A 318
GLY A 321
LEU A 370
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
None
None
GIN  A 600 (-4.7A)
 0.72A 6fnmA-2hz0A:
31.6		 6fnmA-2hz0A:
40.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
ILE A 313
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.78A 6hd4A-2hz0A:
34.3		 6hd4A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.59A 6hd4A-2hz0A:
34.3		 6hd4A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
ILE A 293
ILE A 313
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-3.8A)
 0.78A 6hd4A-2hz0A:
34.3		 6hd4A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_A_STIA604_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		4 / 5 VAL A 289
PHE A 317
MET A 318
GLY A 321
 None
GIN  A 600 (-4.3A)
None
None
 0.34A 6hd4A-2hz0A:
34.3		 6hd4A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
ILE A 313
THR A 315
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.79A 6hd4B-2hz0A:
33.9		 6hd4B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
ILE A 313
THR A 315
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.56A 6hd4B-2hz0A:
33.9		 6hd4B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD4_B_STIB602_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		5 / 6 LEU A 248
VAL A 289
PHE A 317
MET A 318
GLY A 321
 GIN  A 600 ( 4.6A)
None
GIN  A 600 (-4.3A)
None
None
 0.54A 6hd4B-2hz0A:
33.9		 6hd4B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
LEU A 370
ALA A 380
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-4.9A)
 0.64A 6hd6A-2hz0A:
34.3		 6hd6A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 VAL A 256
ALA A 269
GLU A 286
MET A 290
VAL A 299
ILE A 313
THR A 315
PHE A 317
LEU A 370
ALA A 380
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.8A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-3.1A)
 0.48A 6hd6A-2hz0A:
34.3		 6hd6A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		7 / 12 VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
ILE A 313
PHE A 317
 GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-3.8A)
GIN  A 600 (-4.3A)
 0.66A 6hd6A-2hz0A:
34.3		 6hd6A-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		9 / 12 ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
LEU A 370
ASP A 381
 GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
GIN  A 600 (-4.9A)
 0.81A 6hd6B-2hz0A:
33.9		 6hd6B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		10 / 12 LEU A 248
VAL A 256
ALA A 269
GLU A 286
MET A 290
ILE A 293
VAL A 299
THR A 315
PHE A 317
LEU A 370
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.6A)
GIN  A 600 (-3.4A)
GIN  A 600 (-4.3A)
GIN  A 600 (-4.7A)
 0.65A 6hd6B-2hz0A:
33.9		 6hd6B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		8 / 12 LEU A 248
VAL A 256
ALA A 269
LYS A 271
GLU A 286
MET A 290
ILE A 293
PHE A 317
 GIN  A 600 ( 4.6A)
GIN  A 600 ( 4.7A)
GIN  A 600 (-3.1A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.6A)
GIN  A 600 (-3.2A)
GIN  A 600 (-4.5A)
GIN  A 600 (-4.3A)
 0.80A 6hd6B-2hz0A:
33.9		 6hd6B-2hz0A:
92.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HD6_B_STIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2hz0 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1
(Homo
sapiens) 		6 / 7 VAL A 289
ILE A 313
MET A 318
GLY A 321
ARG A 362
ALA A 380
 None
GIN  A 600 (-3.8A)
None
None
None
GIN  A 600 (-3.1A)
 0.77A 6hd6B-2hz0A:
33.9		 6hd6B-2hz0A:
92.50